BG Medicine to Present at ISRTP Workshop: Progress and Barriers to Incorporating Alternative Toxicol11/16/2005WALTHAM, Mass.--(BUSINESS WIRE)--Nov. 16, 2005--BG Medicine today announced that it is scheduled to give a presentation at the International Society of Regulatory Toxicology and Pharmacology Workshop: Progress and Barriers to Incorporating Alternative Toxicological Methods in the U.S. on November 17, 2005 at 1:30pm (ET) at the Marriott Waterfront Hotel in Baltimore, MD. Pieter Muntendam MD, President of BG Medicine, will present under the title "Computational Approach to Systems Toxicology - a Common Path to Mechanism and Biomarkers". Dr. Muntendam will use the recently announced FDA Critical Path collaboration between BG Medicine and the FDA regarding liver toxicity of drugs to illustrate observations and views regarding barriers to innovating toxicity testing. The objective of the Workshop is to explore progress to date in implementing new, revised and alternative toxicological test methods across regulatory evaluation frameworks and decisionmaking programs in the U.S., identify barriers to progress and explore potential bridges to facilitate overcoming such barriers. These barriers may be technical, regulatory, economic or societal. About BG MedicineBG Medicine is pioneering the commercial application of Systems Pharmacology, which is based on scientific advances in the Systems Biology field. Its advanced proprietary platform enables novel paths to new medicines through molecular fingerprinting of genes, proteins, and metabolites combined with powerful bioinformatics integration. For more information about BG Medicine please visit www.bg-medicine.com or contact Scott A. Wallace, Vice President, Business Development at 781-434-0230. NOTE TO EDITORS: See also "FDA and Industry to Collaborate on Better Ways to Predict Liver Toxicity in Human Drug Trials - Part of FDA's Critical Path Initiative to Modernizing Drug Development" released November 2, 2005 by he FDA. Contacts |